Research & Development

Pipeline

Our molecules have the potential to become the first approved JNK inhibitor treatment for IC/PBS directly treating inflammation.

Our molecules

KUSTE BIOPHARMA owns two JNK inhibitors previously extensively studied, and whose safety and efficacy have been demonstrated in a variety of therapeutic applications.

Our molecules have a strong safety profile, they have proven effects in local delivery and can therefore be used by the urology practitioner to treat IC/PBS.

Kuste Biopharma

2 bis rue Tête d’Or
69006 Lyon

5 rue de Castiglione
75001 Paris

+33 (0) 481 133 530
contact@kustebiopharma.com

http://Logo-kuste-Biopharma-Vertical-desktop
Retour haut de page